• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Additive effects of intensive BP control and ACE inhibition on suppression of proteinuria in patients with CKD.强化血压控制和 ACE 抑制对 CKD 患者蛋白尿抑制的累加效应。
J Hum Hypertens. 2023 May;37(5):419-421. doi: 10.1038/s41371-023-00823-z. Epub 2023 Mar 25.
2
Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.血管紧张素转换酶抑制降低早期蛋白尿可预测 CKD 儿童的肾脏存活率。
J Am Soc Nephrol. 2018 Aug;29(8):2225-2233. doi: 10.1681/ASN.2018010036. Epub 2018 Jun 21.
3
Is there added value to adding ARB to ACE inhibitors in the management of CKD?在慢性肾脏病（CKD）的管理中，在血管紧张素转换酶抑制剂（ACE抑制剂）基础上加用血管紧张素Ⅱ受体阻滞剂（ARB）是否具有附加价值？
J Am Soc Nephrol. 2009 Aug;20(8):1666-8. doi: 10.1681/ASN.2008040381. Epub 2008 Sep 5.
4
Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?肾与心脏疾病中肾素-血管紧张素-醛固酮系统的阻断：我们需要阻断到何种程度？
Acta Med Indones. 2008 Jan;40(1):34-7.
5
Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy.钙拮抗剂和血管紧张素转换酶抑制剂对IgA肾病慢性肾衰竭患者的长期影响。
Contrib Nephrol. 1991;90:161-5. doi: 10.1159/000420139.
6
Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.慢性肾脏病：大鼠肾部分切除术后心脏和肾脏血管紧张素转换酶（ACE）2 的表达及 ACE 抑制的作用。
Exp Physiol. 2012 Apr;97(4):477-85. doi: 10.1113/expphysiol.2011.063156. Epub 2011 Dec 23.
7
Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.慢性肾脏病5期的保守治疗：血管紧张素转换酶抑制剂的作用
J Nephrol. 2016 Dec;29(6):809-815. doi: 10.1007/s40620-016-0290-9. Epub 2016 Mar 25.
8
Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.在患有蛋白尿性慢性肾脏病且接受血管紧张素转换酶抑制剂治疗的患者中加用血管紧张素受体阻滞剂。
Clin J Am Soc Nephrol. 2006 Jul;1(4):730-7. doi: 10.2215/CJN.01110905. Epub 2006 May 17.
9
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].[血管紧张素转换酶抑制剂对慢性肾衰竭进展的影响]
Presse Med. 2002 Nov 9;31(36):1714-20.
10
The antiproteinuric effect of ACE inhibition in renal disease.血管紧张素转换酶抑制剂在肾脏疾病中的抗蛋白尿作用。
Pharm World Sci. 1993 Oct 15;15(5):230-2. doi: 10.1007/BF01880632.

引用本文的文献

1
Increased cardiovascular risk in patients with chronic kidney disease.慢性肾脏病患者心血管风险增加。
Herz. 2024 Mar;49(2):95-104. doi: 10.1007/s00059-024-05235-4. Epub 2024 Feb 28.

本文引用的文献

1
From Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options.从蛋白尿到纤维化：病理生理学和治疗选择的最新进展。
Kidney Blood Press Res. 2021;46(4):411-420. doi: 10.1159/000516911. Epub 2021 Jun 15.
2
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.白蛋白尿变化与终末期肾病风险：观察性研究个体参与者水平联盟荟萃分析。
Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8.
3
Intensive blood-pressure control in hypertensive chronic kidney disease.高血压性慢性肾脏病的强化血压控制。
N Engl J Med. 2010 Sep 2;363(10):918-29. doi: 10.1056/NEJMoa0910975.
4
Strict blood-pressure control and progression of renal failure in children.儿童严格血压控制与肾衰竭进展
N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.
5
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).非裔美国人肾脏疾病与高血压研究（AASK）的设计与统计学方面
J Am Soc Nephrol. 2003 Jul;14(7 Suppl 2):S154-65. doi: 10.1097/01.asn.0000070080.21680.cb.
6
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.血压降低及抗高血压药物类别对高血压肾病进展的影响：AASK试验结果
JAMA. 2002 Nov 20;288(19):2421-31. doi: 10.1001/jama.288.19.2421.
7
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.氯沙坦对2型糖尿病肾病患者肾脏和心血管结局的影响。
N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161.
8
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.血管紧张素受体拮抗剂厄贝沙坦对2型糖尿病肾病患者的肾脏保护作用。
N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303.
9
Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.血管紧张素转换酶抑制对2型糖尿病高血压患者的长期影响及代谢控制
Kidney Int. 2000 Feb;57(2):590-600. doi: 10.1046/j.1523-1755.2000.00879.x.
10
Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.赖诺普利通过抑制ACE产生的抗蛋白尿作用的疗效及变异性。
Kidney Int. 1989 Aug;36(2):272-9. doi: 10.1038/ki.1989.190.

强化血压控制和 ACE 抑制对 CKD 患者蛋白尿抑制的累加效应。

Additive effects of intensive BP control and ACE inhibition on suppression of proteinuria in patients with CKD.

机构信息

School of Medicine, University of California San Francisco, San Francisco, CA, USA.

Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

出版信息

J Hum Hypertens. 2023 May;37(5):419-421. doi: 10.1038/s41371-023-00823-z. Epub 2023 Mar 25.

DOI:10.1038/s41371-023-00823-z
PMID:36966224
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10156588/
Abstract

The synergistic effects of RAAS inhibition and intensive blood pressure lowering in reducing proteinuria have not been well studied. We aimed to study this effect using data from the AASK Trial where our data suggest there is an additive and synergistic effect between RAAS inhibition and intensive blood pressure inhibition in reducing proteinuria.

摘要

RAAS 抑制和强化降压在减少蛋白尿方面的协同作用尚未得到很好的研究。我们旨在使用 AASK 试验的数据来研究这种效果，我们的数据表明，在减少蛋白尿方面，RAAS 抑制和强化血压抑制之间存在附加和协同作用。